| Date |
Title |
Rating |
| 2011-09-30 |
Roche inaugurates new clinical supply manufacturing facility in Nutley, N.J. |
None |
| 2011-09-30 |
Cincinnati Children's to conduct first medication clinical trial for pediatric migraine |
None |
| 2011-09-30 |
Array announces results from selumetinib Phase 2 combination study on KRAS-mutant NSCLC |
5 |
| 2011-09-30 |
Small Phase I trial shows HIV vaccine candidate is most powerful to date |
None |
| 2011-09-30 |
Microbicide Trials Network stops tenofovir arm of study after findings show drug less effective than anticipated |
None |
| 2011-09-29 |
Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors |
None |
| 2011-09-29 |
Positive new data from Otonomy's OTO-104 Phase 1b study on Meniere's disease |
None |
| 2011-09-29 |
Cubist plans to move CB-183,315 into Phase 3 trial for treatment of CDAD |
None |
| 2011-09-29 |
DSMB authorizes ACT to proceed with next set of patients in stem cell clinical trials |
5 |
| 2011-09-29 |
Cincinnati Children's to conduct first pediatric migraine medicine clinical trial |
None |
| 2011-09-29 |
Almirall submits linaclotide MAA to EMA for treatment of IBS-C |
None |
| 2011-09-29 |
VOICE HIV prevention trial to discontinue use of tenofovir tablets |
None |
| 2011-09-29 |
Enrollment complete in Rexahn's Archexin Phase II trial for metastatic pancreatic cancer |
None |
| 2011-09-29 |
SanBio initiates SB623 Phase 1/2a clinical trial in ischemic stroke |
4 |
| 2011-09-28 |
Halozyme commences HTI-501 clinical trial for cellulite in women |
None |
| 2011-09-28 |
Phase I clinical trials reveal MVA-B preventive vaccine's immune efficiency against HIV |
None |
| 2011-09-28 |
Adamas begins ADS-5102 Phase 2/3 clinical trial in Parkinson's disease |
None |
| 2011-09-28 |
YM BioSciences begins enrollment in CYT387 Phase II trial for myelofibrosis |
None |
| 2011-09-28 |
Lovastatin appears to be safe, effective for children with neurofibromatosis type 1 |
None |
| 2011-09-28 |
BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR |
2.7 |
| 2011-09-28 |
MicroDose initiates MDT-637 Phase 1 trial in respiratory syncytial virus |
None |
| 2011-09-27 |
22nd Century completes enrollment in X-22 Phase II-B smoking cessation study |
None |
| 2011-09-27 |
The Nation examines rise in unregulated drug trials in South America |
None |
| 2011-09-27 |
HCRI completes enrollment in dual antiplatelet therapy clinical trial |
None |
| 2011-09-27 |
Afraxis to participate in NIH's Therapeutics for Rare and Neglected Disease Program |
None |
| 2011-09-27 |
Arena, Eisai announce new data from lorcaserin Phase 3 clinical trial program |
None |
| 2011-09-27 |
Elevation presents positive data from EP-101 Phase 2a study on COPD at ERS annual meeting |
None |
| 2011-09-27 |
Novartis files marketing authorisation with EMA for NVA237 to treat COPD |
None |
| 2011-09-27 |
Data from YM BioSciences' nimotuzumab clinical trials to be reported at ECCO-ESMO 2011 |
None |
| 2011-09-27 |
Zoledronic acid may extend survival in older breast cancer patients |
None |
| 2011-09-27 |
Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors |
None |
| 2011-09-27 |
Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia |
None |
| 2011-09-27 |
Collegium completes Type A meeting with FDA for COL-003 Phase III chronic low back pain study |
None |
| 2011-09-26 |
Smaller and faster clinical drug trials could improve gains in cancer survival |
None |
| 2011-09-26 |
Pacira announces data from EXPAREL clinical study presented at ASPS 2011 meeting |
None |
| 2011-09-26 |
Zoledronic acid may benefit post-menopausal women with breast cancer |
None |
| 2011-09-26 |
Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL |
None |
| 2011-09-26 |
Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer |
None |
| 2011-09-26 |
JDRF, iCo Therapeutics collaborate for iCo-007 Phase 2 trial in DME |
None |
| 2011-09-26 |
Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma |
None |
| 2011-09-26 |
Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL |
None |
| 2011-09-26 |
Ibandronate controls pain in prostate cancer patients with bone metastases |
None |
| 2011-09-26 |
InterMune reports new data from Esbriet clinical trial on IPF |
None |
| 2011-09-26 |
Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC |
None |
| 2011-09-26 |
Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint |
None |
| 2011-09-26 |
Combination of Afinitor, exemestane reduces risk of breast cancer progression in women |
None |
| 2011-09-26 |
Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials |
None |
| 2011-09-26 |
Combination of abiraterone acetate, prednisone reduces fatigue in men with prostate cancer |
None |
| 2011-09-26 |
Breast cancer drug combination could stop cancer “in its tracks” |
None |
| 2011-09-26 |
Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer |
None |
| 2011-09-26 |
Combination of chemo and radiotherapy in breast cancer: Trial |
None |
| 2011-09-26 |
Drug combo for breast cancer in post-menopausal women shows promise |
None |
| 2011-09-26 |
Zometa bone drug trial in post-menopausal women with breast cancer |
None |
| 2011-09-26 |
Embryonic stem cell therapy for incurable Stargardt eye disease |
4 |
| 2011-09-26 |
The Journal of Pain publishes results from Butrans Transdermal System Phase 3 clinical study |
None |
| 2011-09-26 |
First Radium-223 Chloride Phase III study in prostate cancer |
None |
| 2011-09-26 |
Combination of everolimus, exemestane holds promise against post-menopausal breast cancer |
None |
| 2011-09-26 |
RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome |
None |
| 2011-09-26 |
Letrozole reduces risk of breast cancer recurrences and death in post-menopausal women |
None |
| 2011-09-23 |
EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection |
None |
| 2011-09-23 |
YM BioSciences total revenue decreases to $1.5 million for fiscal 2011 |
None |
| 2011-09-23 |
Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011 |
None |
| 2011-09-23 |
Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV |
None |
| 2011-09-23 |
E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug |
None |
| 2011-09-23 |
Soy protein reduces progression of atherosclerosis in women within 5 years of menopause |
None |
| 2011-09-23 |
Researchers to expand malaria vaccine study after initial trial yields encouraging results |
None |
| 2011-09-23 |
Researchers compare safety and effectiveness of cryotherapy, salicylic acid for verrucae |
None |
| 2011-09-23 |
Levosimendan may effectively improve muscle function in patients with respiratory failure |
None |
| 2011-09-23 |
Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011 |
None |
| 2011-09-22 |
Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma |
None |
| 2011-09-22 |
Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC |
None |
| 2011-09-22 |
Aradigm announces two ciprofloxacin Phase 2b study data on non-CF bronchiectasis |
None |
| 2011-09-22 |
Theraclone initiates TCN-032 Phase 1 trial in influenza A |
None |
| 2011-09-22 |
NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF |
None |
| 2011-09-22 |
S-equol improve appearance of crow's feet skin wrinkles in Japanese menopausal women |
None |
| 2011-09-21 |
HRPR before PCI procedures linked to increased risk of ischemic event in ACS patients |
None |
| 2011-09-21 |
Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for COPD |
None |
| 2011-09-21 |
Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA |
None |
| 2011-09-21 |
Positive results from Orexo's OX219 clinical study on opioid dependence |
None |
| 2011-09-20 |
Niiki Pharma announces positive data from ongoing trial of novel anti-cancer agent NKP-1339 |
None |
| 2011-09-20 |
Gilead’s new 4 in 1 combo HIV pill works |
None |
| 2011-09-20 |
U-M Professor to review data from three prominent studies on heart failure |
None |
| 2011-09-20 |
Gilead’s Quad Phase 3 clinical study in treatment-naïve HIV-1 patients meets 48-week primary objective |
None |
| 2011-09-20 |
New research has potential to alleviate side effects of cancer treatments |
None |
| 2011-09-20 |
Tokai raises $23M in Series D3 financing |
None |
| 2011-09-20 |
Major donors should consider funding for potential malaria vaccine |
None |
| 2011-09-20 |
Top-line data from Santarus' budesonide MMX extended use study on ulcerative colitis |
None |
| 2011-09-20 |
Keryx completes enrollment in Zerenex Phase 3 long-term study for hyperphosphatemia |
5 |
| 2011-09-20 |
Infant formulas fortified with LCPUFA are good for developing brains and hearts |
None |
| 2011-09-20 |
LA BioMed andrologist leads new male contraceptive Phase I clinical study |
None |
| 2011-09-20 |
Scientists pioneer new combination treatment for prostate cancer |
None |
| 2011-09-20 |
Positive data from NovaDigm's NDV-3 vaccine preclinical study on VVC |
None |
| 2011-09-19 |
Preclinical studies shows EmPAC more effective than Taxol |
None |
| 2011-09-19 |
Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD |
None |
| 2011-09-19 |
Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC |
None |
| 2011-09-19 |
Tarsa reports positive data from OSTORA Phase III ORACAL trial for postmenopausal osteoporosis |
5 |
| 2011-09-19 |
Top-line data from Spectrum's SPI-1620 Phase 1 combination study on carcinoma |
None |
| 2011-09-19 |
Inhibitex initiates INX-189 combination Phase 2 trial in HCV-infected genotype 2/3 patients |
None |
| 2011-09-19 |
Aestus to develop ATx09-002 for treatment of neuropathic pain |
None |
| 2011-09-19 |
Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia |
None |
| 2011-09-19 |
Karo Bio receives approval to initiate eprotirome phase III study in HeFH |
None |
| 2011-09-19 |
NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting |
None |
| 2011-09-19 |
Positive data from Tarsa's OSTORA Phase III trial on postmenopausal osteoporosis |
None |
| 2011-09-17 |
Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis |
None |
| 2011-09-17 |
Additional data on safety, tolerability of Cempra's solithromycin to be presented at 51st ICAAC |
None |
| 2011-09-17 |
Multiple abstracts on QNEXA presented at 47th EASD |
None |
| 2011-09-17 |
DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain |
None |
| 2011-09-17 |
BARDA awards Vaxin $21.7M contract to accelerate development of novel anthrax vaccine |
None |
| 2011-09-16 |
ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes |
None |
| 2011-09-16 |
Linagliptin demonstrates durable reductions in blood glucose for T2D adults |
None |
| 2011-09-16 |
Combination of prasugrel plus ASA can treat acute coronary syndrome |
None |
| 2011-09-16 |
Anavex announces ANAVEX pre-clinical data on Alzheimer's disease |
None |
| 2011-09-16 |
Potential new treatment for fragile X syndrome |
None |
| 2011-09-16 |
Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients |
5 |
| 2011-09-16 |
Experimental malaria vaccine shows positive results among children in small Burkina Faso study |
None |
| 2011-09-16 |
Probiotics appear to protect against upper respiratory tract infections |
None |
| 2011-09-16 |
Azithromycin gel may treat borreliosis in humans |
None |
| 2011-09-16 |
Diclofenac in nano-formulated doses provides effective pain relief |
None |
| 2011-09-15 |
CRF announces late breaking trials & first report investigations to be presented at TCT 2011 |
None |
| 2011-09-15 |
Anavex Life Sciences to present data on lead compound for Alzheimer’s at Japan Neuroscience Society |
None |
| 2011-09-15 |
International patient groups anxiously await start of Huntington’s trial |
5 |
| 2011-09-15 |
KAI enters KAI-4169 development and commercialization agreement with Ono |
None |
| 2011-09-15 |
Cempra's solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment |
None |
| 2011-09-15 |
NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma |
None |
| 2011-09-15 |
Novo Nordisk's insulin degludec reduces blood sugar in patients with type 2 diabetes |
5 |
| 2011-09-15 |
Patients with hepatitis C may benefit from 24 week telaprevir-based regimen |
None |
| 2011-09-15 |
Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis |
None |
| 2011-09-15 |
First effective blood-stage vaccine against malaria |
5 |
| 2011-09-15 |
NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C |
None |
| 2011-09-15 |
SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease |
None |
| 2011-09-15 |
Scientist granted over $138,000 to explore Vitamin C therapy in sepsis |
5 |
| 2011-09-15 |
Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes |
None |
| 2011-09-14 |
Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections |
None |
| 2011-09-14 |
Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer |
None |
| 2011-09-14 |
Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study |
None |
| 2011-09-14 |
New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011 |
None |
| 2011-09-14 |
Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma |
None |
| 2011-09-14 |
Lexicon's LX4211 clinical data presented at EASD annual meeting |
None |
| 2011-09-14 |
VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting |
None |
| 2011-09-14 |
ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE |
None |
| 2011-09-14 |
Acceleron commences ACE-536 Phase 1 clinical trial in anemia |
None |
| 2011-09-13 |
New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress |
None |
| 2011-09-13 |
Researchers use MRI and PET/CT to assess safety, efficacy of heart drug dalcetrapib |
None |
| 2011-09-13 |
Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference |
None |
| 2011-09-13 |
ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM |
None |
| 2011-09-12 |
Clinical trial planned in Australia and the USA to help patients with ‘orphan’ disease |
4.3 |
| 2011-09-12 |
Sanofi's Lyxumia achieves primary efficacy endpoint in study of patients uncontrolled on metformin |
None |
| 2011-09-12 |
Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer |
None |
| 2011-09-12 |
BioSante reports top-line results from LibiGel PK study for HSDD in postmenopausal women |
None |
| 2011-09-12 |
Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease |
None |
| 2011-09-12 |
Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC |
3 |
| 2011-09-12 |
InteRNA, Silence partner to develop novel microRNA therapeutics for cancer |
None |
| 2011-09-12 |
Recruitment complete in Moberg Derma's MOB-015 phase II study for nail fungus |
None |
| 2011-09-12 |
Roche initiates Phase 1 clinical trial of investigational drug for Down syndrome |
5 |
| 2011-09-12 |
UMSOM to receive FDA approval for whole parasite malaria vaccine clinical trials |
None |
| 2011-09-12 |
Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer |
None |
| 2011-09-09 |
Sangamo's SB-728-T Phase 1 study data on HIV/AIDS to be presented at ICAAC conference |
4 |
| 2011-09-09 |
Fewer doses of Cervarix vaccine may be as efficacious as standard three-dose regimen |
None |
| 2011-09-09 |
Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban |
None |
| 2011-09-09 |
Sagene completes SPI-1972 pre-IND meeting with FDA for erectile dysfunction |
None |
| 2011-09-09 |
Positive results from Sanaria PfSPZ Vaccine initial Phase 1 trial on malaria |
None |
| 2011-09-08 |
OptiNose chooses BioClinica's advanced imaging and IWR solutions for clinical trials |
None |
| 2011-09-08 |
Lilly, Boehringer Ingelheim to present latest data from diabetes portfolio at 47th EASD meeting |
None |
| 2011-09-08 |
Better communication needed with at-risk communities for HIV vaccine trials |
None |
| 2011-09-08 |
Adding azithromycin to usual daily treatment for COPD reduces acute exacerbations by 27% |
None |
| 2011-09-07 |
Top-line results from Teva-Alcobra MG01CI Phase II trial for ADHD |
None |
| 2011-09-07 |
Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA |
None |
| 2011-09-07 |
Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects |
None |
| 2011-09-07 |
Cancer Research UK opens olaparib-temozolomide combination Phase I trial in glioblastoma |
None |
| 2011-09-07 |
ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme |
None |
| 2011-09-07 |
GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052 |
None |
| 2011-09-07 |
Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data |
None |
| 2011-09-06 |
Positive results from BDSI's BEMA Buprenorphine/Naloxone formulation Phase 1 study on opioid dependence |
None |
| 2011-09-06 |
Enrollment complete in DURECT's POSIDUR Phase III study for post-surgical pain |
None |
| 2011-09-06 |
Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints |
None |
| 2011-09-06 |
Shiva Biomedical, CorMedix to extend CRMD001 phase III trial in chronic kidney disease |
None |
| 2011-09-06 |
ICS, Quintiles enter agreement with Pacira to support launch of EXPAREL |
None |
| 2011-09-06 |
Pharmasset reports SVR results from PSI-7977 phase 2b combination study on HCV genotype 1 |
None |
| 2011-09-06 |
NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease |
None |
| 2011-09-06 |
Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma |
None |
| 2011-09-06 |
Chondroitin sulfate decreases pain and improves hand function in patients with OA |
None |
| 2011-09-06 |
BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer |
None |
| 2011-09-05 |
Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks |
None |
| 2011-09-05 |
Gilead to amend design of ongoing clinical trials against chronic hepatitis C |
None |
| 2011-09-03 |
SWOG selects four cancer researchers for 2011 Young Investigator Training Course |
None |
| 2011-09-02 |
Dr. Reddy’s initiates DRL-17822 Phase II study in type II dyslipidemia |
None |
| 2011-09-02 |
New meta-analysis reaffirms safety profile of aspirin for pain relief, fever |
None |
| 2011-09-02 |
Valproic acid may increase survival for brain tumor patients |
None |
| 2011-09-02 |
New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress |
None |
| 2011-09-02 |
UTHealth to study BMS-820836 in Phase II trial for major depressive disorder |
None |